I've been thinking a lot about what the three most significant trials could be for my practice among the many presented this year at #EuroPCR. In general, I prefer it when the primary endpoint is presented for the first time. This is my selection, feel free to disagree.

Great choice, Davide, thank you very much ! With the KISS trial, we have an important piece of puzzle for a stepwise provisional strategy in non-LM bifurcations. Now we need to do the LM-KISS, Bernard Chevalier, we are looking forward to it 💯

Great choices and high quality summary (as always). My personal recommendation would be to always include the NI margin in the statement of non-inferiority. Also, are the %stenoses flipped on the last results slide (REFORM) or was the NI margin ludicrously large?

Thanks David. :) All papers are unpublished so far and the noninferiority margins are not reported (sic). Yes, I also suspect they are quite large. In REFORM, the biolimus-coated balloon was inferior, the percentages are from the original slides and should be correct.

@w_jyg So Biolimus A9 coated balloon was inferior to current paclitaxel DCB technology right?

Great ! Thank for share this !!!

Lovely summaries- thank you!

Thanks for sharing!

@Sticchi_Alex Nicely done !